ALKEM Alkem Lab Q4 FY26 results (Jan–Mar 2026) and concall
Alkem Laboratories reported a landmark FY26 with EBITDA crossing INR3,000 crores, driven by robust revenue growth and margin expansion. The company saw strong performance in both India and international markets, highlighted by the successful launch of semaglutide. While facing headwinds from rising input costs and a higher tax rate in FY27, management remains focused on execution, strategic launches, and profitability, with the Occlutech acquisition expected to close soon.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 14.6%, net profit down 22.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 3,415 | 3,374 | 3,144 | 3,371 | 4,001 +17% | 3,737 +11% | 3,603 +15% |
| EBITDA | 753 | 759 | 391 | 739 | 921 +22% | 828 +9% | 517 +32% |
| Net profit | 702 | 641 | 322 | 668 | 779 +11% | 653 +2% | 251 −22% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
